Tocilizumab for the treatment of severe coronavirus disease 2019

Tocilizumab, an interleukin‐6 inhibitor, may ameliorate the inflammatory manifestations associated with severe coronavirus disease 2019 (COVID‐19) and thus improve clinical outcomes. This was a retrospective review of patients with laboratory‐confirmed severe COVID‐19 who received tocilizumab and co...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Med Virol
Main Authors: Alattar, Rand, Ibrahim, Tawheeda B. H., Shaar, Shahd H., Abdalla, Shiema, Shukri, Kinda, Daghfal, Joanne N., Khatib, Mohamed Y., Aboukamar, Mohamed, Abukhattab, Mohamed, Alsoub, Hussam A., Almaslamani, Muna A., Omrani, Ali S.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7267594/
https://ncbi.nlm.nih.gov/pubmed/32369191
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jmv.25964
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados